Trevi director granted 35,000 stock options
Trevi Therapeutics director Edward T. Mathers received a new stock option grant covering 35,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Trevi Therapeutics director Edward T. Mathers received a new stock option grant covering 35,000 shares of common stock. The nonstatutory option has an exercise price of $13.45 per share and expires on June 2, 2036.
According to the terms, the option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as Mathers continues to serve as a director, employee, or consultant of Trevi Therapeutics.
Insider Trade Summary
Grant/Award: 35,000 shares
Grant/Award
1 txn
Insider
Mathers Edward T
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Nonstatutory Stock Option (right to buy) | 35,000 | $0.00 | $0.00 |
Holdings After Transaction:
Nonstatutory Stock Option (right to buy) — 35,000 contracts (Direct)
Footnotes (1)
- F1. This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Key Figures
Option grant size: 35,000 options
Exercise price: $13.45 per share
Expiration date: June 2, 2036
+3 more
6 metrics
Option grant size
35,000 options
Nonstatutory stock option covering 35,000 shares
Exercise price
$13.45 per share
Conversion or exercise price of the option
Expiration date
June 2, 2036
Option expiration for the nonstatutory stock option
Underlying shares
35,000 shares
Underlying Trevi common stock linked to the option
Grant date
June 3, 2026
Date on which the option was granted
Post-transaction derivative holdings
35,000 options
Total options held following this reported transaction
Key Terms
Nonstatutory Stock Option, exercise price, expiration date, annual meeting of stockholders, +1 more
5 terms
Nonstatutory Stock Option financial
"Nonstatutory Stock Option (right to buy)"
A nonstatutory stock option (also called a non-qualified stock option) is an employee or contractor right to buy company shares at a set price that does not qualify for special tax treatment. When exercised, the difference between the market price and the set price is treated as ordinary income for the recipient and usually triggers payroll tax and withholding. For investors, these options matter because they create potential share dilution, affect reported compensation costs, and influence the timing of when new shares enter the market—similar to a coupon that lets someone buy stock at a discount but results in an immediate tax bill.
exercise price financial
"conversion_or_exercise_price": "13.4500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-06-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders of the Issuer"
continued service financial
"subject to the recipient's continued service as a director, employee or consultant"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Trevi Therapeutics (TRVI) report for Edward T. Mathers?
Trevi Therapeutics reported a stock option grant to director Edward T. Mathers. He received a nonstatutory option for 35,000 shares of common stock, structured as compensation, rather than an open-market purchase or sale of existing shares.
What are the key terms of Edward T. Mathers’ new Trevi Therapeutics (TRVI) stock option?
The option covers 35,000 shares at an exercise price of $13.45. It is a nonstatutory stock option that expires on June 2, 2036, giving Mathers the right to buy Trevi common shares at that fixed price if vested.
When do Edward T. Mathers’ Trevi Therapeutics (TRVI) options vest?
The option is scheduled to fully vest based on time and service conditions. Vesting occurs on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting held after that date, subject to continued service.
How many Trevi Therapeutics (TRVI) derivative securities does Edward T. Mathers hold after this transaction?
Following this transaction, Mathers holds 35,000 stock options as reported. These options relate to an equal number of underlying Trevi common shares and represent his derivative position from this specific grant disclosed in the Form 4.
What service requirement is tied to Edward T. Mathers’ Trevi Therapeutics (TRVI) option vesting?
Vesting depends on Mathers’ continued service with Trevi Therapeutics. He must remain a director, employee, or consultant through the vesting date, which is the earlier of one year from grant or the next annual stockholder meeting after grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates